These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 36542262)

  • 41. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
    Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
    Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
    Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
    Kim KS; Hong S; Ahn HY; Park CY
    Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.
    Ayada I; van Kleef LA; Alferink LJM; Li P; de Knegt RJ; Pan Q
    Liver Int; 2022 Feb; 42(2):277-287. PubMed ID: 34953098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: A cross sectional analytical study.
    Herath RP; Siriwardana SR; Ekanayake CD; Abeysekara V; Kodithuwakku SUA; Herath HP
    PLoS One; 2019; 14(4):e0215326. PubMed ID: 30978266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
    Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population.
    Deng D; George J; Pasupathy D; Wah Cheung N
    Diabetes Res Clin Pract; 2021 Apr; 174():108757. PubMed ID: 33744378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review.
    Leca BM; Lagojda L; Kite C; Karteris E; Kassi E; Randeva HS; Kyrou I
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):335-348. PubMed ID: 38860684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between cataract and fatty liver diseases from a nationwide cross-sectional study in South Korea.
    Kang KH; Shin D; Ryu IH; Kim JK; Lee IS; Koh K; Yoo TK
    Sci Rep; 2024 Jan; 14(1):77. PubMed ID: 38167592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
    Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort.
    Zeng J; Jin Q; Yang J; Yang RX; Zhang RN; Zhao J; Fan JG
    Hepatol Int; 2023 Dec; 17(6):1416-1428. PubMed ID: 37728728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.